- Home
- PMAX vs CRIS Comparison
PMAX vs CRIS Comparison
Compare PMAX & CRIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PMAX | CRIS |
|---|---|---|
| Founded | 2019 | 2000 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5M | 14.6M |
| IPO Year | 2024 | 2000 |
Fundamental Metrics
Financial Performance| Metric | PMAX | CRIS |
|---|---|---|
| Price | $2.35 | $1.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.50 |
| AVG Volume (30 Days) | ★ 1.7M | 116.9K |
| Earning Date | 09-23-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $4,799,100.00 | ★ $11,650,000.00 |
| Revenue This Year | N/A | $6.13 |
| Revenue Next Year | N/A | $8.44 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 13.56 |
| 52 Week Low | $1.56 | $1.02 |
| 52 Week High | $23.17 | $4.50 |
Technical Indicators
Market Signals| Indicator | PMAX | CRIS |
|---|---|---|
| Relative Strength Index (RSI) | 49.25 | 36.32 |
| Support Level | $2.17 | $1.14 |
| Resistance Level | $2.97 | $1.41 |
| Average True Range (ATR) | 0.35 | 0.10 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 30.72 | 2.94 |
Price Performance
Historical ComparisonAbout PMAX Powell Max Limited
Powell Max Ltd is an financial communications services provider. Its financial communications services cover a full range of financial printing, corporate reporting, communications and language support services from inception to completion, including typesetting, proofreading, translation, design, printing, electronic reporting, newspaper placement and distribution. It operates in a single business segment which is the provision of corporate financial communications and financial printing services. All operations are carried in Hong Kong.
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.